Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Mayne Pharma Group ( (AU:MYX) ) has shared an update.
Mayne Pharma Group Limited announced the cessation of certain securities, specifically 529,129 performance rights and 695,322 options, due to the expiry of options or other convertible securities without exercise or conversion as of September 30, 2025. This cessation may impact the company’s capital structure and could have implications for stakeholders, as it reflects adjustments in the company’s financial instruments and potential changes in shareholder value.
The most recent analyst rating on (AU:MYX) stock is a Hold with a A$5.50 price target. To see the full list of analyst forecasts on Mayne Pharma Group stock, see the AU:MYX Stock Forecast page.
More about Mayne Pharma Group
Mayne Pharma Group Limited operates in the pharmaceutical industry, focusing on the development and manufacturing of branded and generic pharmaceutical products. The company is known for its expertise in drug delivery systems and its market focus includes both domestic and international markets.
YTD Price Performance: 16.10%
Average Trading Volume: 283,214
Technical Sentiment Signal: Buy
Current Market Cap: A$468.8M
Find detailed analytics on MYX stock on TipRanks’ Stock Analysis page.